Evaluation and Treatment of Hirsutism in Premenopausal Women.

GUIDELINE TITLE

Evaluation and Treatment of Hirsutism in Premenopausal Women

DEVELOPER

Endocrine Society, Androgen Excess and Polycystic Ovary Syndrome Society, European Society of Endocrinology

RELEASE DATE

March 2018

PRIOR VERSION

February 5, 2008

FUNDING SOURCE

Endocrine Society

TARGET POPULATION

Premenopausal women with excess hair growth

MAJOR RECOMMENDATIONS

DIAGNOSIS: Obtain a random serum total testosterone measurement to assess for androgen excess in all women with an abnormal hirsutism score (weak recommendation, low-quality evidence). Obtain an early-morning 17-hydroxyprogesterone measurement in all women with elevated testosterone and in women with hirsutism who are at high risk of congenital adrenal hyperplasia (weak recommendation; low-quality evidence). Do not measure androgen levels in women with normal menses and a normal hirsutism score (weak recommendation; low-quality evidence). PHARMACOLOGIC TREATMENT: Start with pharmacologic therapy and add direct hair removal methods for women with a normal hirsutism score but patient-important hirsutism despite shaving or plucking (weak recommendation; very low-quality evidence). In women who are not seeking pregnancy, oral contraceptive pills (OCPs) are recommended as initial therapy (weak recommendation; low-quality evidence). Either OCPs or antiandrogens are acceptable initial therapies in women who are not sexually active, have undergone permanent sterilization, or are using long-acting reversible contraception (weak recommendation; very low-quality evidence). Combination therapy with an antiandrogen is recommended if patient-important hirsutism persists despite 6 months of monotherapy with an OCP (weak recommendation; low-quality evidence).